VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Orexigen Therapeutics, Inc. (OREX): The Bottom Line
VIVUS, Inc. (NASDAQ:VVUS)' Qsymia has not received the unconditional consumer love that investors were hoping.
Posts Tagged ‘Arena Pharmaceuticals Inc. (ARNA)’
Merck & Co., Inc. (MRK), AVEO Pharmaceuticals, Inc. (AVEO): This Week in Biotech
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Arena Pharmaceuticals, Inc. (ARNA): U.S. Approved Obesity Drug Derailed in EU
Most, and probably all, of that decline is because of the European decision, or lack thereof. Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (ARNA): Here’s What You Missed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY) & Other Names To Know: A Full Breakdown
Investing in biotech companies can be intimidating, especially for investors without a science background. But there's hope.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX): Have Drugmakers Found the Panacea for Obesity? (Part I)
After a gap of several years, there seems to be a candidate in the obesity drug market that could turn out to be a long-term winner.
Biopharma News: Arena Pharmaceuticals, Inc. (ARNA)’s Update, New VIVUS, Inc. (VVUS) Deal & More
Editor's Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Johnson & Johnson (NYSE:JNJ), Orexigen Therapeutics, Inc.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS) & The Panacea For Obesity?
In the previous part of this article, I discussed the potential obesity market and some promising drugs on the scene.
Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (SNY), Arena Pharmaceuticals, Inc. (ARNA) & Three Companies Ripe for a Takeover
One of the nice things about owning biotech companies is the large number of acquisitions in the sector.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Some Key Catalysts Approaching
The obesity stocks are perhaps some of the most discussed and followed stocks in the entire biotechnology sector.
Trending News: Exxon Mobil Corporation (XOM), Arena Pharmaceuticals, Inc. (ARNA), QUALCOMM, Inc. (QCOM)
Editor's Note: Related tickers: Exxon Mobil Corporation (NYSE:XOM), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), 3M Co (NYSE:MMM), Akamai Technologies, Inc.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Anti-Obesity Stocks Are Attractively Priced
The obesity market was one of the most attractive sectors a year ago, and the shares of companies developing anti-obesity drugs were the pharmaceutical sector's hottest properties...
Herbalife Ltd. (HLF), Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS): Stocks to Know for the Obesity Epidemic
Obesity rates have been steadily growing in the developed world, in particular in the US, which has the world’s highest rate of obesity.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): The US’s Hidden Obesity Epidemic
The United States is the fattest country in the world -- and I'm not talking about our wallets, folks! According to the Centers for Disease Control and Prevention, a disheartening...
Theravance Inc (THRX): Here’s One Thing To Know About The Stock Today
Theravance Inc (NASDAQ:THRX) has experienced a decrease in support from the world's most elite money managers of late, but insiders on the whole appear bullish.
Arena Pharmaceuticals, Inc. (ARNA), Biogen Idec Inc. (BIIB): More Than an Obesity Drug Company
Arena Pharmaceuticals, Inc.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), and How Doctors Actually Diagnose Obesity
The obesity crisis in America is a hotly debated topic. According to the Centers for Disease Control and Prevention, more than 35% of adults in the U.S.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Ten Flabbergasting Costs of America’s Obesity Epidemic
Obesity is costing us big time. Three times more Americans are obese now than were in 1960. Six times more Americans are now extremely obese than a half-century ago.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Which Obesity Drug Will Boost Your Portfolio?
In 2012, the FDA approved two obesity drugs for use in the United States. One drug, named "Belviq", is from Arena Pharmaceuticals, Inc.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), Orexigen Therapeutics, Inc. (OREX): The Big Weight-Drug Wait
"Wait" seems to be the operative word for the obesity drug industry these days. Investors in VIVUS, Inc.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Is Obesity Really a Dangerous Disease?
Obesity drugmakers Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , VIVUS, Inc. (NASDAQ:VVUS) , and Orexigen Therapeutics, Inc.
5 Hidden Causes of Obesity: Arena Pharmaceuticals, Inc. (ARNA), VIVUS Inc. (VVUS)
Obesity-drug makers Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS Inc. (NASDAQ:VVUS), and Orexigen Therapeutics, Inc.
Arena Pharmaceuticals, Inc. (ARNA) Faces Europe’s Obesity Opportunity: VIVUS Inc. (VVUS)
You can't find a hotter topic in health care than obesity.
Cancer Prevention and the Hidden Risk of Obesity: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)
Obesity has become one of the most prevalent diseases in the United States.
This Investment Just Became More Attractive: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)
The FDA approval of obesity drugs has been received with a lot of investor enthusiasm. The FDA has thus far approved two drugs: Qsymia from VIVUS, Inc.
Tick Tock Goes the Obesity Clock: Orexigen Therapeutics, Inc. (OREX), VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)
The Food and Drug Administration made the company run a clinical trial to confirm that there weren't any heart-related complications with Contrave.
Questcor Pharmaceuticals Inc (QCOR) Will Carry On its Rise: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)
Some companies were happy to see the end of 2012. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) was one of them.
Is the Wait Over? – Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX)
The obesity industry is new on the stock block, but it has already become one of the most followed industries in our market.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Is There a “First-Mover” Advantage in Biotech?
The early bird gets the worm. Business gurus might not use that old phrase, but many of them tout the principle behind it.
3 Bio-Pharmaceuticals You Can’t Ignore: Arena Pharmaceuticals, Inc. (ARNA), VIVUS Inc. (VVUS)
The last year has been a stellar one for the biotechnology industry.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals Inc. (ARNA): Just 12,500% More Growth for an Obesity Blockbuster
Of course, that's kind of like talking about an huge gnat. I'm sure they probably exist, but you're working from such a small base, that the added size doesn't amount to much.
VIVUS, Inc. (VVUS) Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Hot Off the Press: VIVUS, Inc. (VVUS)’s Appeal for EU Approval Denied
Days after launching its obesity drug Qsymia in the U.S. last September, VIVUS, Inc.
What Is It With Arena Pharmaceuticals, Inc. (ARNA) and the EMA?
Regardless of FDA approval, safety issues have been a great concern with regulators and medical practitioners when it comes to obesity drugs.
The FDA Made Biotech Investing Harder (But More Lucrative): Johnson & Johnson (JNJ)
For instance, it's hard to make money on shoo-in Food and Drug Administration approvals. The approval is already reflected in the price.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Will There Ever Be an Obesity Drug Blockbuster?
Investors are anxiously waiting for the launch of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai's obesity drug Belviq, which will match up with VIVUS, Inc.
Sanofi SA (SNY) & ISIS Pharmaceuticals, Inc. (ISIS) Out-Limbo Aegerion Pharmaceuticals, Inc. (AEGR) in HoFH
I was admittedly never very good when it came to limbo because I'm not very flexible and I'm all legs. Sanofi SA (ADR) (NYSE:SNY) and ISIS Pharmaceuticals, Inc.
2 Growth Catalysts Could Push Arena Pharmaceuticals, Inc. (ARNA) Higher In 2013
An advisory committee to the European Medicines Agency has asked for more information on heart valve issues, psychiatric side effects, and tumors that were detected during studies...
Why Arena Pharmaceuticals, Inc. (ARNA) Shares Lost Weight
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Is it Time to Buy Vivus on the Dip?
From an investing standpoint, Vivus, Inc. (NASDAQ:VVUS) appeared to get ahead of itself again earlier this year, as hype in the obesity market reached a fever pitch.
Arena Pharma (ARNA), Vivus (VVUS): Which Hedge Funds Made the Wrong Pharma Bets?
Since the end of 2Q, the very popular biopharma companies, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) and Vivus, Inc.
Why is Orbimed Backing Out of Amarin?
Orbimed Advisors, managed by Samuel Isaly, is a hedge fund with a focus on the healthcare sector.
Arena Pharmaceuticals Inc. (ARNA): What to Expect from Earnings
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) gets its turn in the earnings parade Thursday when it releases its quarterly report after the closing bell.
Arena Pharmaceuticals (ARNA), VIVUS (VVUS), Amarin (AMRN) See Stocks Tied Together Again
Three pharmaceutical companies - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc.
Insider Sales: Arena Pharmaceuticals, VIVUS Inc, Amarin Corporation
There has been an interesting trend among three noteworthy pharmaceutical companies like Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc.
Arena Pharmaceuticals vs. Vivus: Which Is a Better Weight Loss Drug for Investors?
Arena Pharmaceuticals (NASDAQ:ARNA) and Vivus (NASDAQ:VVUS) are battling in the minds of investors as each promises a drug with the potential to cause weight loss- a sure moneymaker...
Can Vivus Inc. Ride Qsymia to Market Success and Big Returns?
Since last week's news that Vivus, Inc. (NASDAQ:VVUS) received FDA approval for its obesity drug Qsymia, the raging battle between Vivus and Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.: With Belviq Approval, Now What?
In the pharmaceutical sector of the market, many eyes have been on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and its fierce competitor, Vivus, Inc.
